Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

575 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Preference for involvement in treatment decisions and request for prognostic information in newly diagnosed patients with higher-risk myelodysplastic syndromes.
Efficace F, Gaidano G, Sprangers M, Cottone F, Breccia M, Voso MT, Caocci G, Stauder R, Di Tucci AA, Sanpaolo G, Selleslag D, Angelucci E, Platzbecker U, Mandelli F. Efficace F, et al. Among authors: breccia m. Ann Oncol. 2014 Feb;25(2):447-54. doi: 10.1093/annonc/mdt557. Ann Oncol. 2014. PMID: 24478321 Free article.
Accuracy of physician assessment of treatment preferences and health status in elderly patients with higher-risk myelodysplastic syndromes.
Caocci G, Voso MT, Angelucci E, Stauder R, Cottone F, Abel G, Nguyen K, Platzbecker U, Beyne-Rauzy O, Gaidano G, Invernizzi R, Molica S, Criscuolo M, Breccia M, Lübbert M, Sanpaolo G, Buccisano F, Ricco A, Palumbo GA, Niscola P, Zhang H, Fenu S, La Nasa G, Mandelli F, Efficace F. Caocci G, et al. Among authors: breccia m. Leuk Res. 2015 Aug;39(8):859-65. doi: 10.1016/j.leukres.2015.05.012. Epub 2015 Jun 12. Leuk Res. 2015. PMID: 26120100
Time for a new era in the evaluation of targeted therapies for patients with chronic myeloid leukemia: inclusion of quality of life and other patient-reported outcomes.
Efficace F, Cocks K, Breccia M, Sprangers M, Meyers CA, Vignetti M, Baccarani M, Mandelli F; GIMEMA and EORTC Quality of Life Group. Efficace F, et al. Among authors: breccia m. Crit Rev Oncol Hematol. 2012 Feb;81(2):123-35. doi: 10.1016/j.critrevonc.2011.02.007. Epub 2011 Mar 24. Crit Rev Oncol Hematol. 2012. PMID: 21435899 Review.
The impact of comorbidity on health-related quality of life in elderly patients with chronic myeloid leukemia.
Efficace F, Rosti G, Breccia M, Cottone F, Giesinger JM, Stagno F, Iurlo A, Russo Rossi A, Luciano L, Martino B, Galimberti S, Turri D, Bergamaschi M, Tiribelli M, Fava C, Angelucci E, Mandelli F, Baccarani M. Efficace F, et al. Among authors: breccia m. Ann Hematol. 2016 Jan;95(2):211-9. doi: 10.1007/s00277-015-2541-6. Epub 2015 Nov 7. Ann Hematol. 2016. PMID: 26546359
Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: an observational patient-centered outcome study.
Efficace F, Baccarani M, Rosti G, Cottone F, Castagnetti F, Breccia M, Alimena G, Iurlo A, Rossi AR, Pardini S, Gherlinzoni F, Salvucci M, Tiribelli M, Vignetti M, Mandelli F. Efficace F, et al. Among authors: breccia m. Br J Cancer. 2012 Sep 4;107(6):904-9. doi: 10.1038/bjc.2012.348. Epub 2012 Aug 7. Br J Cancer. 2012. PMID: 22871884 Free PMC article.
Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib.
Efficace F, Baccarani M, Breccia M, Cottone F, Alimena G, Deliliers GL, Baratè C, Specchia G, Di Lorenzo R, Luciano L, Turri D, Martino B, Stagno F, Dabusti M, Bergamaschi M, Leoni P, Simula MP, Levato L, Fava C, Veneri D, Sica S, Rambaldi A, Rosti G, Vignetti M, Mandelli F. Efficace F, et al. Among authors: breccia m. Leukemia. 2013 Jul;27(7):1511-9. doi: 10.1038/leu.2013.51. Epub 2013 Feb 18. Leukemia. 2013. PMID: 23417029
Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population.
Efficace F, Baccarani M, Breccia M, Alimena G, Rosti G, Cottone F, Deliliers GL, Baratè C, Rossi AR, Fioritoni G, Luciano L, Turri D, Martino B, Di Raimondo F, Dabusti M, Bergamaschi M, Leoni P, Simula MP, Levato L, Ulisciani S, Veneri D, Sica S, Rambaldi A, Vignetti M, Mandelli F; GIMEMA. Efficace F, et al. Among authors: breccia m. Blood. 2011 Oct 27;118(17):4554-60. doi: 10.1182/blood-2011-04-347575. Epub 2011 Jul 12. Blood. 2011. PMID: 21750313 Free article.
Erythropoietin levels and erythroid differentiation parameters in patients with lower-risk myelodysplastic syndromes.
Gurnari C, Latagliata R, Buccisano F, Piciocchi A, Fenu S, Mancini S, Fianchi L, Criscuolo M, Sarlo C, Romano A, Falconi G, Niscola P, Di Veroli A, Breccia M, Piccioni A, Aloe-Spiriti MA, Lo-Coco F, Voso MT; GROM-L (Gruppo Romano-Laziale MDS); GROM-L (Gruppo Romano-Laziale MDS). Gurnari C, et al. Among authors: breccia m. Leuk Res. 2018 Aug;71:89-91. doi: 10.1016/j.leukres.2018.07.002. Epub 2018 Jul 10. Leuk Res. 2018. PMID: 30029156 No abstract available.
575 results